INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.58 USD | -0.63% |
|
+8.22% | -3.07% |
| Jun. 05 | InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904 | CI |
| May. 08 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 407K 443K | Sales 2025 * | 1.37M 1.49M | Capitalization | 85.62M 93.19M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -50.07M | Net income 2025 * | -61M -66.39M | EV / Sales 2024 * | 83.7 x |
| Net cash position 2024 * | 51.55M 56.11M | Net cash position 2025 * | 7.3M 7.94M | EV / Sales 2025 * | 57.1 x |
| P/E ratio 2024 * |
-1.96
x | P/E ratio 2025 * |
-1.7
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on InflaRx N.V.
More recommendations
More press releases
More news
| 1 week | +8.22% | ||
| Current month | +10.49% | ||
| 1 month | +14.49% | ||
| 3 months | -11.73% | ||
| 6 months | +12.86% | ||
| Current year | -3.07% |
1 week
1.37
1.68
1 month
1.171.72
Current year
1.172.10
1 year
1.144.70
3 years
0.787.25
5 years
0.789.70
10 years
0.7853.10
| Managers | Title | Age | Since |
|---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 1.58 | 0.00% | 95,521 |
| 24-06-04 | 1.58 | 0.00% | 197,190 |
| 24-06-03 | 1.58 | +10.49% | 278,577 |
| 24-05-31 | 1.43 | 0.00% | 298,879 |
| 24-05-30 | 1.43 | -2.05% | 276,209 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotes
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.454
EUR
Average target price
8.375
EUR
Spread / Average Target
+475.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.07% | 93.04M | |
| +18.72% | 125B | |
| +14.53% | 109B | |
| -2.88% | 24.74B | |
| +2.18% | 22.67B | |
| -10.09% | 18.14B | |
| -41.04% | 16.67B | |
| -11.83% | 16.64B | |
| +1.46% | 13.45B | |
| +24.22% | 11.32B |
- Stock Market
- Equities
- IFRX Stock
